Corvus Pharmaceuticals Stock
Corvus Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Richard A. Miller
- Employees
- 37
- Market cap
- $801 M
- IPO
- 23/03/2016
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for…
Corvus Pharmaceuticals stock: price history
1D
-3.4%
1W
-9.5%
1M
-22.2%
6M
-43.1%
YTD
+23.6%
1Y
+24.4%
2Y
+29.5%
5Y
+92.3%
10Y
-35.9%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~6% stronger price swings than usual
Ask the agents about Corvus Pharmaceuticals
Analyst assessment of Corvus Pharmaceuticals
PRICE TARGET LOW
US$40.00
CONSENSUS
US$40.00
MEDIAN
US$40.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
12
BUY
1
HOLD
0
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 13/03/2026
Corvus Pharmaceuticals stock metrics
P/E
-14.88
P/B
3.9
EV/EBITDA
-15.19
RETURN ON EQUITY
-8.0%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.0%
FLOAT SHARES
64,795,637
AVG. DAILY VOLUME (30D)
1,229,291
Insider transactions (SEC)
Moore David Scott
MILLER RICHARD A MD
MILLER RICHARD A MD
Institutional holders
Comparable stocks
Frequently asked questions about Corvus Pharmaceuticals stock
What does Corvus Pharmaceuticals do?
Corvus Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Richard A. Miller, the company employs around 37 people.
The IPO was on 23/03/2016; the stock trades on NASDAQ under the ticker CRVS.
What do analysts say about Corvus Pharmaceuticals stock?
13 analysts rate the stock, the consensus is Buy (as of 13/03/2026).
The average price target is US$40.00, ranging from US$40.00 to US$40.00, with a median of US$40.00.
This is an external assessment, not a statement by Market Jury.
When does Corvus Pharmaceuticals report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 6% stronger than usual.
Does Corvus Pharmaceuticals pay a dividend?
No, Corvus Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Corvus Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Corvus Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Corvus Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.